Status:
COMPLETED
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
Lead Sponsor:
GlaxoSmithKline
Conditions:
Atherosclerosis
Eligibility:
All Genders
50-80 years
Phase:
PHASE2
Brief Summary
A study in patients with atherosclerosis to assess safety, effect and PK of rilapladib vs. placebo over 12 weeks of dosing.
Detailed Description
Study LP2105521 is a randomized, double-blind, placebo-controlled, parallel-group study to examine the safety, tolerability, and effects of rilapladib on plasma Lp-PLA2 activity, plaque inflammation, ...
Eligibility Criteria
Inclusion
- Capable of giving written informed consent and able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.
- Male or female, aged 50 to 80 years inclusive, at screening.
- Females must be of non-childbearing potential
- Body weight ≥ 50 kg and BMI within the range 19-35 kg/m2
- Documented atherosclerotic vascular disease (e.g. prior MI, prior revascularization, peripheral arterial disease, carotid disease, or cerebrovascular disease) and clinically stable for at least 6 months
- If diabetic, have well controlled diabetes, defined for the purpose of this study as HbA1c ≤8% or FPG ≤200 mg/dL
- Evidence of plaque inflammation \[carotid artery or ascending aorta plaque inflammation defined as a tissue to background ratio (TBR) ≥ 1.6\]
- On a stable dose of a statin for 3 months prior to screening with no evidence of statin intolerance
Exclusion
- Recent (i.e., \<6 months from Screening Visit) CV event defined as ST-elevation MI or non-ST-elevation MI, confirmed by cardiac enzyme elevation and ECG changes, coronary revascularization (PCI or CABG), stroke of any etiology, resuscitated sudden death, prior carotid surgery or stenting procedure
- Evidence of clinical instability or abnormal clinical laboratory findings prior to randomization that, in the opinion of the Investigator, makes the subject unsuitable for the study.
- Exposure to substantial radiation within the past 12 months
- Planned cardiac surgery (e.g., CABG, valve repair or replacement, or aneurysmectomy), PCI or major non-cardiac surgery within the study period
- Current inadequately controlled hypertension (blood pressure ≥160 mmHg systolic or ≥100 mmHg diastolic) on a stable dose of anti-hypertensive medication
- Diabetics taking injectable insulin at screening
- Serum triglycerides \>400 mg/dL, LDLc \>130 mg/dL
- Recent (\<1 month) or ongoing acute infection.
- History of chronic inflammatory disease
- Recently received (\<1 month) or currently receiving oral or injectable corticosteroids, or regular use of nasal, inhaled or topical corticosteroids.
- Subjects who will commence, or who are likely to commence regular treatment with oral, non-steroidal anti-inflammatory drugs (NSAIDs) from screening until study completion
- Currently receiving oral or injectable potent CYP3A4 inhibitor(s)
- History of chronic viral hepatitis or other chronic hepatic disorders; or ALT or AST \>1.5 x ULN, or alkaline phosphatase or total bilirubin \>1.5 x ULN of laboratory reference range at Screen
- Renal impairment with serum creatinine \>2.0 mg/dl or history of kidney transplant or status post nephrectomy.
- History of myopathy or inflammatory muscle disease, or elevated total CPK at screening
- History of severe heart failure defined as NYHA class III or IV or those with known severe left ventricular dysfunction (ejection fraction\<30%) regardless of symptomatic status
- History of adult asthma (or reactive airway disease) manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s)
- History of anaphylaxis, anaphylactoid (resembling anaphylaxis) reactions or severe allergic responses
- History of malignancy within the past 2 years.
- A history of glaucoma or any other findings in the baseline eye exam
- Current life-threatening condition other than vascular disease that may prevent a subject from completing the study
- QTc interval ≥450msec at screening or ≥480 msec for subjects with bundle branch block
- History of drug abuse within the past 6 months
- Previous exposure to rilapladib.
- Contraindication to MRI scanning
- Use of an investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication
- Any other subject the Investigator deems unsuitable for the study
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00695305
Start Date
November 1 2008
End Date
May 1 2010
Last Update
December 1 2016
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Boston, Massachusetts, United States, 02114
2
GSK Investigational Site
Brockton, Massachusetts, United States, 02301
3
GSK Investigational Site
Haverhill, Massachusetts, United States, 01830
4
GSK Investigational Site
Linden, New Jersey, United States, 07036